Company Overview
Company Type: Private Company
Website: www.norgenbiotek.com
Number of Employees: 25
Year Founded: 1998
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Norgen Biotek Corp., a biotechnology company, provides tools for genomic and proteomic research to the life sciences and pharmaceutical industry. The company offers RNA purification products, including RNA, RNA/DNA/protein, RNA/protein, animal tissue RNA, microRNA, cytoplasmic and nuclear RNA, plant/fungi RNA, and FFPE RNA purification kits, as well as RNA cleanup and concentration kits. It also provides DNA purification products, which comprise plant/fungi DNA, milk bacterial DNA, fungi/yeast genomic DNA, genomic DNA, soil DNA, yeast genomic DNA, urine DNA, and urine bacteria DNA isolation kits, as well as endotoxin removal kits; and protein purification products, such as urine protein concentration kits, inclusion body protein purification kits, and abundant serum protein depletion kits. In addition, the company offers soil and water kits, including water RNA/DNA and FFPE RNA/DNA purification kits; concentration and desalting kits, including detergent cleanup kit, on-column proteolytic digestion kits, and DNA and RNA ladders; DNA and RNA markers; diagnostic kits for the diagnosis of human, food-borne, and plant pathogens; reagents; and plastics and filtration devices. Further, it provides adenovirus vector construction, viral diagnostic, and custom plasmid amplification and purification services. Furthermore, the company offers urine-based sample preparation products to preserve, concentrate, and purify macromolecules, such as DNA, RNA, microRNA, proteins, exfoliated cells, and microorganisms. It serves academia, pharmaceutical/biotech companies, and government institutions. It distributes its products in Brazil, Israel, Malaysia, Switzerland, Belgium, Italy, Portugal, Taiwan, Canada, Japan, South Korea, the United Kingdom, China, Spain, and Germany. Norgen Biotek Corp. has a strategic partnership with Diversigen Inc. The company was founded in 1998 and is based in Thorold, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 1.9
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 25
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Haj-Ahmad, Yousef
Chief Executive Officer and President


Primary Industry Classification
Biotechnology


Primary Office Location
3430 Schmon Parkway | Thorold, ON | L2V 4Y6 | Canada
Phone: 905-227-8848   Fax: 905-227-1061


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Key Developments
Date
Event Type
Headline
Feb-18-2020
Client Announcements
Norgen Biotek Corp. Offers First-Class Products to Assist Researchers in the Study and Molecular Diagnosis of the 2019 Novel Coronavirus (Covid-19) Outbreak
Jul-10-2018
Strategic Alliances
Diversigen Inc. and Norgen Biotek Corp. Partner to Offer End-To-End Solutions for Microbiome Sample and Analysis Research
Jul-13-2017
Product-Related Announcements
Norgen Biotek Corp Launches New Portfolio for Next Generation Sequencing, Including Library Preparation Kits and Full Ngs Service Offering
Mar-07-2016
Client Announcements
Norgen Biotek Inks Supplier Deal with Biodesix
Nov-02-2015
Product-Related Announcements
Norgen Biotek Launches Novel Kits


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 04:13 AM
Norgen Biotek Corp.
Norgen Biotek Corp
Reports
41
GlobalData

Jul 14, 2023 04:54 AM
Norgen Biotek Corp.
Norgen Biotek Corp - Medical Devices Product Pipeline Summary
Reports
22
GlobalData

Jun 16, 2023 01:07 AM
Norgen Biotek Corp.
Norgen Biotek Corp
Reports
41
GlobalData

Jun 09, 2023 10:56 AM
Norgen Biotek Corp.
Norgen Biotek Corp - Medical Devices Product Pipeline Summary
Reports
22
GlobalData

Mar 16, 2023 02:20 AM
Norgen Biotek Corp.
Norgen Biotek Corp
Reports
41
GlobalData

Mar 10, 2023 03:09 AM
Norgen Biotek Corp.
Norgen Biotek Corp - Medical Devices Product Pipeline Summary
Reports
22
GlobalData

Dec 14, 2022 01:24 AM
Norgen Biotek Corp.
Norgen Biotek Corp
Reports
41
GlobalData

Dec 09, 2022 09:35 PM
Norgen Biotek Corp.
Norgen Biotek Corp - Medical Devices Product Pipeline Summary
Reports
22
GlobalData

Sep 16, 2022 07:08 AM
Norgen Biotek Corp.
Norgen Biotek Corp
Reports
41
GlobalData

Sep 15, 2022 08:40 AM
Norgen Biotek Corp.
Norgen Biotek Corp - Medical Devices Product Pipeline Summary
Reports
22


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
DNA Purification Kit, Protein Purification Kits, RNA Purification Kit, The Milk Bacterial DNA Isolation Kit, The Saliva DNA Isolation Kit, The Urine Bacteria DNA Isolation Kit, Urine Concentration and Preservation Device

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Haj-Ahmad, Yousef
Chief Executive Officer and President
905-227-8848
905-227-1061
yha@norgenbiotek.com
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
